Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review
- PMID: 10724107
- DOI: 10.1097/00004647-200003000-00001
Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review
Abstract
Several groups have provided evidence that positron emission tomography (PET) and single-photon emission computed tomography (SPECT) neuroreceptor imaging techniques might be applied to measure acute fluctuations in dopamine (DA) synaptic concentration in the living human brain. Competition between DA and radioligands for binding to D2 receptor is the principle underlying this approach. This new application of neuroreceptor imaging provides a dynamic measurement of neurotransmission that is likely to be informative to our understanding of neuropsychiatric conditions. This article reviews and discusses the body of data supporting the feasibility and potential of this imaging paradigm. Endogenous competition studies performed in rodents, nonhuman primates, and humans are first summarized. After this overview, the validity of the model underlying the interpretation of these imaging data is critically assessed. The current reference model is defined as the occupancy model, since changes in radiotracer binding potential (BP) are assumed to be directly caused by changes in occupancy of D2 receptors by DA. Experimental data supporting this model are presented. The evidence that manipulation of DA synaptic levels induces change in the BP of several D2 radiotracers (catecholamines and benzamides) is unequivocal. The fact that these changes in BP are mediated by changes in DA synaptic concentration is well documented. The relationship between the magnitude of BP changes measured with PET or SPECT and the magnitude of changes in DA concentration measured by microdialysis supports the use of these noninvasive techniques to measure changes in neurotransmission. On the other hand, several observations remain unexplained. First, the amphetamine-induced changes in the BP of D2 receptor antagonists [123I]IBZM and [11C]raclopride last longer than amphetamine-induced changes in DA extracellular concentration. Second, nonbenzamide D2 receptor antagonists, such as spiperone and pimozide, are not affected by changes in DA release, or are affected in a direction opposite to that predicted by the occupancy model. Similar observations are reported with D1 radiotracers. These results suggest that the changes in BP following changes in DA concentration might not be fully accounted by a simple occupancy model. Specifically, the data are reviewed supporting that agonist-mediated receptor internalization might play an important role in characterizing receptor-ligand interactions. Finally, it is proposed that a better understanding of the mechanism underlying the effects observed with benzamides is essential to develop this imaging technique to other receptor systems.
Similar articles
-
Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.Synapse. 2009 Jun;63(6):447-61. doi: 10.1002/syn.20628. Synapse. 2009. PMID: 19217025
-
Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights.Q J Nucl Med. 2001 Jun;45(2):124-38. Q J Nucl Med. 2001. PMID: 11476162 Review.
-
Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.Synapse. 1997 Jan;25(1):1-14. doi: 10.1002/(SICI)1098-2396(199701)25:1<1::AID-SYN1>3.0.CO;2-H. Synapse. 1997. PMID: 8987142
-
Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.Synapse. 1992 Mar;10(3):177-84. doi: 10.1002/syn.890100302. Synapse. 1992. PMID: 1532675
-
Imaging dopamine transmission in schizophrenia. A review and meta-analysis.Q J Nucl Med. 1998 Sep;42(3):211-21. Q J Nucl Med. 1998. PMID: 9796369 Review.
Cited by
-
Novel voxelwise residual analysis of [11C]raclopride PET data improves detection of low-amplitude dopamine release.J Cereb Blood Flow Metab. 2024 May;44(5):757-771. doi: 10.1177/0271678X231214823. Epub 2023 Nov 16. J Cereb Blood Flow Metab. 2024. PMID: 37974315 Free PMC article.
-
Striatal dopamine tone is positively associated with body mass index in humans as determined by PET using dual dopamine type-2 receptor antagonist tracers.medRxiv [Preprint]. 2023 Sep 28:2023.09.27.23296169. doi: 10.1101/2023.09.27.23296169. medRxiv. 2023. PMID: 37886556 Free PMC article. Preprint.
-
Amphetamine-induced dopamine release in rat: Whole-brain spatiotemporal analysis with [11C]raclopride and positron emission tomography.J Cereb Blood Flow Metab. 2024 Mar;44(3):434-445. doi: 10.1177/0271678X231210128. Epub 2023 Oct 26. J Cereb Blood Flow Metab. 2024. PMID: 37882727 Free PMC article.
-
Amphetamine pretreatment blunts dopamine-induced D2/D3-receptor occupancy by an arrestin-mediated mechanism: A PET study in internalization compromised mice.Neuroimage. 2023 Dec 1;283:120416. doi: 10.1016/j.neuroimage.2023.120416. Epub 2023 Oct 20. Neuroimage. 2023. PMID: 37866759 Free PMC article.
-
Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies.J Psychopharmacol. 2023 Nov;37(11):1058-1069. doi: 10.1177/02698811231200881. Epub 2023 Oct 9. J Psychopharmacol. 2023. PMID: 37811803 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources